INHIBITION OF SWEATING BY SCOPOLAMINE.
Craig, F. N., Cummings, E. G., Paul Sussman
Abstract
Craig, F. N., Cummings, E. G., Paul Sussman
Abstract
The purpose of this study was to determine the effects of scopolamine hydrobromide on sweating in man. The methods employed previously with atropine sulfate were applied to scopolamine hydrobromide to compare these two drugs with respect to the dose required to inhibit sweating. Two different sweat rates were obtained by exposing three men at rest to environmental temperatures of 105 and 125 F. The effects of scopolamine on body temperatures, heart rate, and sweating were qualitatively similar to those previously obtained with atropine. It was concluded that scopolamine hydrobromide is from two to three times more potent than atropine sulfate in its effects on sweating and heart rate in man. (Author)
A significance statement is not available in the OpenAlex record.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
The purpose of this study was to determine the effects of scopolamine hydrobromide on sweating in man. The methods employed previously with atropine sulfate were applied to scopolamine hydrobromide to compare these two drugs with respect to the dose required to inhibit sweating. Two different sweat rates were obtained by exposing three men at rest to environmental temperatures of 105 and 125 F. The effects of scopolamine on body temperatures, heart rate, and sweating were qualitatively similar to those previously obtained with atropine. It was concluded that scopolamine hydrobromide is from two to three times more potent than atropine sulfate in its effects on sweating and heart rate in man. (Author)
Key concepts: Scopolamine Hydrobromide, Atropine sulfate, Atropine, Scopolamine, SWEAT, Hydrobromide, Heart rate, Parasympatholytic